BioPhorum

BioPhorum Sustainability welcomes Moderna Inc to BioPhorum. We are delighted that you are joining this group, which together has the unique ability to build a strong coalition for change for an entire industry, and apply it to the greatest challenge of our generation.

Our mission is to act as a voice of the industry to enable delivery of the industry’s sustainability ambition quickly and effectively.
To lead innovative teams who have the capability and credibility to create consensus and ultimately drive real change that benefits people and planet. https://okt.to/S1XnOI

This paper is for all quality professionals who are working to understand the key areas where real-time release testing (RTRT) will impact the pharmaceutical quality system. It addresses the compliance challenges of RTRT and continued compliance with current good manufacturing standards.

Read more and download here - https://okt.to/Jl5KRr

Clarifying the misunderstandings associated with visual inspections, this paper talks about the key subjects of regulations, criticality and detectability, probability of detection, qualification vs. detection, and – importantly – why criticality and detectability of defects do not correlate.

Read more here - https://okt.to/zBaG8q

Introducing BioPhorum Council – taking back increased value to your organization

You can listen to the podcast here - https://okt.to/7vPDNO

Clare Simpson, Client Service Director, talks us through the concept of BioPhorum Council. What initiated the idea, and what opportunities will it provide? How will the Council feed into the work being advanced at the phorum and workstream level and who should be participating? Listen now to learn about this exciting launch, and then get in touch by contacting [email protected]

We assessed whether companies evaluated process parameters differently for clinical trial stages and commercialization. Read the full list of survey responses, included in a supporting information file alongside the article which discusses how worst-case conditions for a viral clearance step differ depending on its stage in a manufacturing process.

You can read more here - https://okt.to/kqjTwE

If you wish to receive our latest monthly newsletter you can sign up here - https://okt.to/esnRS1

Building and leveraging senior connections to help accelerate the industry vision further through BioPhorum membership is at the heart of the BioPhorum Council’s raison d’etre. Do you want to be involved?

You can view here - https://okt.to/ueHFT3

If you wish to receive our latest monthly newsletter you can sign up here - https://okt.to/6Kj8DA

While progress is being made, we must increase the pace of sustainability transformation across the value chain. This need has led to a demand from BioPhorum members for a harmonized industry approach across the entire biopharmaceutical sector to accelerate progress – the result is BioPhorum’s environmental sustainability roadmap.

You can download the roadmap here - https://okt.to/0dxQMS

With a key aim to ensure we have a common language and understanding across the industry, the Long-Range Planning Workstream is expanding its team to include those with knowledge of long-range planning processes. If you can share your knowledge and want to learn from other world-leading experts, then read on.

Read more here - https://okt.to/0RZv3f

Explaining the current state of integration models and the challenges faced by the industry, this paper is essential reading for business leaders in biomanufacturers and contract organizations, as well as digital leaders, integration, and IT solution providers providing operational and analytics systems.

Read more here - https://okt.to/WVxrko

There is still time to register for our upcoming webinar - Supporting particle investigations with risk-based decision-making

Wednesday, 30 November 2022 - 10:00 - 11:00 EST,
15-00 - 16:00 BST, 16:00 - 17:00 CET

The presence of visible particles in parenteral medicines is a perennial issue for the industry. How do companies manage particles when they are found, especially when atypical in nature? What can companies do to assess the risk of a particle, and how can a particle impact the future of a batch of a biopharmaceutical product?

Follow the link for more details and to register here - https://okt.to/FSgc4P

An informative and inspiring consolidation of the benchmarks, position papers, guidance documents, assessment tools, industry user requirements, study results, and roadmaps produced in the last twelve months.
Read more here - https://okt.to/XeYjyJ